Dr. Crombie founded PRISMARC.org to extend earlier studies on HIV/AIDS at Weill-Cornell Medical Center. She discovered a binding domain on HIV-1 for TSP-1, a protein abundant in saliva. She then showed anti-HIV-1 inhibitory activity of TSP-1, and is inventor on the patent of a vaginal microbicide derivative. Her ground-breaking work places protection against HIV-1 infection under a woman’s control.
As Director of PRISMARC, Dr. Crombie developed a program of projects based upon a novel theory that depletion of TSP-1 by viral particles leads to specific AIDS illnesses. Her hypothesis predicts that restoration of TSP-1 may mitigate AIDS disease.
PRISMARC’s mission targets young scientists with literature review skills and critical grantsmanship focused on PRISMARC’s unique niche. Dr. Crombie brings together a collaborative of colleagues worldwide in the biotechnology industry. She also maintains a weekly blog on the PRISMARC website.
Reflecting on her education and training, Dr. Crombie received training at The Johns Hopkins Schools of Public Health and Medicine, Memorial Sloan-Kettering Cancer Center, and Rockefeller Research Laboratories in New York. Dr. Crombie earned her Bachelor’s degree in Biology and Art from USNA-Goucher, and her Ph.D. in Molecular Cell Biology and Genetics from Weill-Cornell Graduate School of Medical Sciences.
For more information, please visit www.prismarc.org
